Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:artesunate
|
| gptkbp:activities |
inhibits parasite growth
|
| gptkbp:appointed_by |
intravenous route
|
| gptkbp:approves |
gptkb:World_Health_Organization
non-severe malaria |
| gptkbp:associated_with |
improved clinical outcomes
reduced mortality rapid parasite clearance |
| gptkbp:can_be_used_with |
gptkb:lumefantrine
gptkb:mefloquine sulfadoxine-pyrimethamine |
| gptkbp:caused_by |
allergic reactions
fever seizures skin rash hypoglycemia thrombocytopenia hemolysis |
| gptkbp:clinical_trial |
Phase III
emergency treatment high when administered intravenously |
| gptkbp:contraindication |
hypersensitivity to artesunate
|
| gptkbp:developed_by |
gptkb:artemisinin
Chinese researchers |
| gptkbp:duration |
approximately 24 hours
|
| gptkbp:formulation |
sterile solution
|
| https://www.w3.org/2000/01/rdf-schema#label |
artesunate injection
|
| gptkbp:interacts_with |
other antimalarial drugs
|
| gptkbp:is_available_in |
vials
|
| gptkbp:is_available_on |
generic medication
|
| gptkbp:is_monitored_by |
blood pressure
kidney function liver function blood glucose |
| gptkbp:is_used_for |
treating severe malaria
|
| gptkbp:lifespan |
approximately 1 hour
|
| gptkbp:manager |
intramuscular
|
| gptkbp:marketed_as |
various brand names
|
| gptkbp:produced_by |
pharmaceutical companies
|
| gptkbp:side_effect |
gptkb:fandom
dizziness headache nausea vomiting hypotension |
| gptkbp:storage |
room temperature
|
| gptkbp:suitable_for |
patients with severe renal impairment
WHO guidelines patients with severe liver disease pregnant women in first trimester |
| gptkbp:treatment |
severe Plasmodium falciparum malaria
|
| gptkbp:used_in |
gptkb:Southeast_Asia
gptkb:sub-Saharan_Africa tropical regions |